{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:46:36Z","timestamp":1764510396685},"reference-count":78,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.critrevonc.2011.02.007","type":"journal-article","created":{"date-parts":[[2011,4,14]],"date-time":"2011-04-14T20:50:44Z","timestamp":1302814244000},"page":"123-135","source":"Crossref","is-referenced-by-count":22,"title":["Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes"],"prefix":"10.1016","volume":"81","author":[{"given":"F.","family":"Efficace","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Cocks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Sprangers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mandelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2011.02.007_bib0005","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0010","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/asheducation-2008.1.418","article-title":"Chronic myeloid leukaemia: an historical perspective","author":"Deininger","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajh.21380","article-title":"First-line therapy for chronic myeloid leukaemia: past, present and future","volume":"84","author":"Pavlovsky","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0020","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0025","first-page":"114","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","author":"Deininger","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"June (24)","key":"10.1016\/j.critrevonc.2011.02.007_bib0030","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"ENESTnd Investigators Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0035","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukaemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"September (6)","key":"10.1016\/j.critrevonc.2011.02.007_bib0040","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.critrevonc.2011.02.007_bib0045","doi-asserted-by":"crossref","DOI":"10.3310\/hta8280","article-title":"Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukemia in chronic phase: a systematic review and economic analysis","volume":"8","author":"Dalziel","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0050","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.1994.12.3.608","article-title":"Lessons learned from measuring health-related quality of life in oncology","volume":"12","author":"Osoba","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0055","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1200\/JCO.1999.17.6.1654","article-title":"Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone","volume":"17","author":"Osoba","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0060","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1080\/10428190500244183","article-title":"Quality of life in chronic lymphocytic leukemia: a neglected issue","volume":"46","author":"Molica","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0065","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2008.03.017","article-title":"Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials \u2013 a systematic review to evaluate the added value in supporting clinical decision making","volume":"44","author":"Efficace","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0305-7372(03)00142-7","article-title":"Short- and long-term effects of acute myeloid leukemia on patient health-related quality of life","volume":"30","author":"Redaelli","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0075","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.1996.14.2.671","article-title":"Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology","volume":"14","author":"ASCO","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0080","unstructured":"National Cancer Institute: The NCI Strategic Plan for Leading the Nation. To eliminate the suffering and death due to cancer. National Institutes of Health Publication No. 06-5773. http:\/\/strategicplan.nci.nih.gov\/pdf\/nci_2007_strategic_plan.pdf."},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0085","series-title":"Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims","author":"US Food and Drug Administration","year":"2009"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0090","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(02)00876-8","article-title":"Quality of life in patients undergoing systemic therapy for advanced breast cancer","volume":"3","author":"Bottomley","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0095","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1200\/JCO.2003.01.203","article-title":"Health-related quality of life in non small-cell lung cancer: methodologic issues in randomized controlled trials","volume":"21","author":"Bottomley","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2003.10.012","article-title":"Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomized controlled trials","volume":"40","author":"Efficace","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0105","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cncr.11065","article-title":"Health-related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials","volume":"97","author":"Efficace","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0110","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3324\/haematol.11710","article-title":"Health-related quality of life and symptom assessment in clinical research of patients with haematological malignancies: where are we now and where do we go from here?","volume":"92","author":"Efficace","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0115","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2003.12.121","article-title":"Beyond the development of health-related quality of life (HRQOL) measures. A checklist for evaluating HRQOL outcomes in cancer clinical trials-does HRQOL evaluation in prostate cancer research inform clinical decision-making?","volume":"21","author":"Efficace","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0120","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/SLA.0b013e3181e623db","article-title":"A systematic review of the clinical evidence to guide treatment recommendations in breast reconstruction based on patient-reported outcome measures and health-related quality of life","volume":"252","author":"Winters","year":"2010","journal-title":"Ann Surg"},{"issue":"July (19)","key":"10.1016\/j.critrevonc.2011.02.007_bib0125","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1200\/JCO.2005.05.2951","article-title":"Health-related quality of life measurement in randomized clinical trials in surgical oncology","volume":"24","author":"Blazeby","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0130","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.ejca.2008.05.008","article-title":"Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials","volume":"44","author":"Cocks","year":"2008","journal-title":"Eur J Cancer"},{"issue":"June (18)","key":"10.1016\/j.critrevonc.2011.02.007_bib0135","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.2008.20.2069","volume":"27","author":"Bottomley","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0140","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S1470-2045(05)70432-0","article-title":"Health-related quality of life in patients with glioblastoma: a randomised controlled trial","volume":"6","author":"Taphoorn","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0145","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"Van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0150","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/(SICI)1097-0258(19980315\/15)17:5\/7<517::AID-SIM799>3.0.CO;2-S","article-title":"Missing quality of life data in cancer clinical trials: serious problems and challenges","volume":"17","author":"Bernhard","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0155","series-title":"Quality of life assessment in clinical trials: methods and practice","first-page":"227","article-title":"Methods of anaysis for longitudinal studies of health-related quality of life","author":"Fairclough","year":"1998"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2011.02.007_bib0165","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1212\/WNL.45.5.947","article-title":"Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia","volume":"45","author":"Pavol","year":"1995","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.critrevonc.2011.02.007_bib0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0020-7489(96)00025-9","article-title":"A substantive theory of quality of life of adults with chronic leukaemia","volume":"34","author":"Bertero","year":"1997","journal-title":"Int J Nurs Stud"},{"issue":"8","key":"10.1016\/j.critrevonc.2011.02.007_bib0175","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0145-2126(97)00026-X","article-title":"Quality of life in young patients with chronic myelocytic leukaemia during intensive treatment including interferon","volume":"21","author":"Stalfelt","year":"1997","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2011.02.007_bib0180","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.thj.6200251","article-title":"Treatment of CML using IFN-alpha: impact on quality of life","volume":"4","author":"Homewood","year":"2003","journal-title":"Hematol J"},{"issue":"12","key":"10.1016\/j.critrevonc.2011.02.007_bib0185","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1182\/blood-2003-10-3605","article-title":"Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups","volume":"103","author":"Kluin-Nelemans","year":"2004","journal-title":"Blood"},{"issue":"Spring (2)","key":"10.1016\/j.critrevonc.2011.02.007_bib0190","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.neuropsych.16.2.185","article-title":"Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy","volume":"16","author":"Scheibel","year":"2004","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"3","key":"10.1016\/j.critrevonc.2011.02.007_bib0195","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00002820-199806000-00008","article-title":"The meaning of quality of life and the effects of unrelated donor bone marrow transplants for chronic myeloid leukemia in adult long-term survivors","volume":"21","author":"Molassiotis","year":"1998","journal-title":"Cancer Nurs"},{"issue":"5","key":"10.1016\/j.critrevonc.2011.02.007_bib0200","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00002820-199910000-00002","article-title":"Quality of life in patients with chronic myeloid leukemia after unrelated donor bone marrow transplantation","volume":"22","author":"Molassiotis","year":"1999","journal-title":"Cancer Nurs"},{"issue":"9","key":"10.1016\/j.critrevonc.2011.02.007_bib0205","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2002.06.077","article-title":"Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation","volume":"20","author":"Kiss","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2011.02.007_bib0215","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1176\/appi.psy.45.5.378","article-title":"Predictors of 1-year survival assessed at the time of bone marrow transplantation","volume":"45","author":"Chang","year":"2004","journal-title":"Psychosomatics"},{"issue":"4","key":"10.1016\/j.critrevonc.2011.02.007_bib0210","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/cncr.20431","article-title":"Depression, cigarette smoking, and hematopoietic stem cell transplantation outcome","volume":"101","author":"Chang","year":"2004","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2011.02.007_bib0220","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/sj.bmt.1704638","article-title":"A single-centre assessment of long-term quality-of-life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase","volume":"34","author":"Hayden","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.critrevonc.2011.02.007_bib0225","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1176\/appi.psy.46.1.34","article-title":"Psychosocial function after hematopoietic stem cell transplantation","volume":"46","author":"Chang","year":"2005","journal-title":"Psychosomatics"},{"issue":"11","key":"10.1016\/j.critrevonc.2011.02.007_bib0230","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study","volume":"21","author":"Hahn","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0235","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0240","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0245","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-3999(86)90069-3","article-title":"The Psychosocial Adjustment to Illness Scale","volume":"30","author":"Derogatis","year":"1986","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0250","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression Scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0255","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short form health survey (SF-36): I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0260","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1300\/J077V10N03_05","article-title":"Development of the satisfaction with life domains scale for cancer","volume":"10","author":"Baker","year":"1992","journal-title":"J Psychosoc Oncol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0265","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bmt.1700806","article-title":"Quality of life following bone marrow transplantation: a comparison of patient reports with population norms","volume":"19","author":"Sutherland","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0270","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/JCO.1984.2.5.472","article-title":"Measuring the quality of life of cancer patients: the Functional Living Index\u2014Cancer: development and validation","volume":"2","author":"Schipper","year":"1984","journal-title":"J Clin Oncology"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0275","series-title":"Cognitive therapy of depression","author":"Beck","year":"1979"},{"issue":"February (1)","key":"10.1016\/j.critrevonc.2011.02.007_bib0280","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1023\/B:QURE.0000015297.91158.01","article-title":"The functional assessment of cancer therapy-BRM (FACT-BRM) a new tool for the assessment of quality of life in patients treated with biologic response modifiers","volume":"13","author":"Bacik","year":"2004","journal-title":"Qual Life Res"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0285","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol: a new facility for the measurement of health-related quality of life","volume":"16","author":"The EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0290","series-title":"How to score and interpret single-item health status measures: a manual for users of the SF-8 Health Survey","author":"Ware","year":"2001"},{"issue":"July (1)","key":"10.1016\/j.critrevonc.2011.02.007_bib0295","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2008-10-182592","article-title":"Quality of life after allogeneic hematopoietic cell transplantation","volume":"114","author":"Pidala","year":"2009","journal-title":"Blood"},{"issue":"January (3)","key":"10.1016\/j.critrevonc.2011.02.007_bib0300","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2011.02.007_bib0305","first-page":"143","article-title":"Randomized comparison of imatinib 800mg vs imatinib 400mg\u00b1IFN in newly diagnosed BCR\/ABL positive chronic phase CML: analysis of molecular remission at 12 months","volume":"114","author":"Hehlmann","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0310","first-page":"114","author":"Baccarani","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0315","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdl494","article-title":"Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making","volume":"18","author":"Efficace","year":"2007","journal-title":"Ann Oncol"},{"issue":"August (12)","key":"10.1016\/j.critrevonc.2011.02.007_bib0320","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.ejca.2005.05.007","article-title":"Health related quality of life outcomes in cancer clinical trials","volume":"41","author":"Bottomley","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0325","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4065\/77.6.561","article-title":"Assessing meaningful change in quality of life over time: a users\u2019 guide for clinicians","volume":"77","author":"Sprangers","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.critrevonc.2011.02.007_bib0330","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0335","article-title":"The symptom burden of chronic myelogenous leukemia (CML)","volume":"112","author":"Williams","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"June (4)","key":"10.1016\/j.critrevonc.2011.02.007_bib0340","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1524-4733.2008.00470.x","article-title":"Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report","volume":"12","author":"Coons","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0345","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/009286150203600127","article-title":"Patient-reported outcomes: the example of health related quality of life\u2014a European guidance document for the improved integration of health related quality of life assessment in the drug regulatory process","volume":"36","author":"Chassany","year":"2002","journal-title":"Drug Inf J"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0350","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/BF00540022","article-title":"Guidelines for reporting results of quality of life assessments in clinical trials","volume":"5","author":"Staquet","year":"1996","journal-title":"Qual Life Res"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0355","first-page":"25","article-title":"Building quality of life assessment into cancer treatment studies","volume":"6","author":"Gotay","year":"1992","journal-title":"Oncology (Huntingt)"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0360","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jnci\/84.8.575","article-title":"Quality-of-life assessment in cancer treatment protocols: research issues in protocol development","volume":"84","author":"Gotay","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0365","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0959-8049(96)00412-1","article-title":"Quality of life assessment in clinical trials\u2014guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience, MRC Cancer Trials Office","volume":"33","author":"Fayers","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0370","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0959-8049(00)00007-1","article-title":"Quality of life evaluation in oncological clinical trials \u2013 the EORTC model","volume":"36","author":"Haes de","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0375","series-title":"Education program for the 14th congress of the European Hematology Association (EHA)","first-page":"89","article-title":"Designing and interpreting quality-of-life and other patient-reported outcomes in clinical trials","author":"Efficace","year":"2009"},{"key":"10.1016\/j.critrevonc.2011.02.007_bib0380","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications","volume":"117","author":"Pinilla-Ibarz","year":"2011","journal-title":"Cancer"},{"issue":"May (10)","key":"10.1016\/j.critrevonc.2011.02.007_bib0385","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/jnci\/djq097","article-title":"Impact of cultural and linguistic factors on symptom reporting by patients with cancer","volume":"102","author":"Wang","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"February (3)","key":"10.1016\/j.critrevonc.2011.02.007_bib0390","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2141.2009.07992.x","article-title":"Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention","volume":"148","author":"Pidala","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842811000539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842811000539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T16:25:03Z","timestamp":1543854303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842811000539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1040842811000539"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2011.02.007","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}